. .

 
Zuruecksetzen

Suchergebnis - Biogen

Zeit Titel
02.08 13:48dpa-AFX: *DZ BANK RAISES FAIR VALUE FOR BIOGEN TO 219 (214) USD - 'HOLD'
02.08 13:48dpa-AFX: *DZ BANK HEBT FAIREN WERT FÜR BIOGEN AUF 219 (214) USD - 'HALTEN'
01.08 13:31dpa-AFX: Biogen Q2 Results Top Estimates; Boosts FY24 Outlook
01.08 13:17dpa-AFX: *BIOGEN Q2 TOTAL REVENUE $2.465 BLN; NET INCOME ATTRIBUTABLE TO BIOGEN $583.6 MLN
01.08 13:16dpa-AFX: *BIOGEN NOW SEES FY OPERATING INCOME TO GROW AT A MID- TO HIGH-TEEN PERCENTAGE
01.08 13:15dpa-AFX: *BIOGEN NOW SEES FY TOTAL REVENUE TO DECLINE BY A LOW-SINGLE DIGIT PERCENTAGE
01.08 13:15dpa-AFX: *BIOGEN LIFTS FY VIEW: NOW SEES NON-GAAP EPS TO BE BETWEEN $15.75 AND $16.25
01.08 13:05dpa-AFX: *BIOGEN Q2 GAAP EPS $4.00; NON-GAAP EPS $5.28
30.07 23:15dpa-AFX: GNW-Adhoc: New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International
30.07 16:10dpa-AFX: Biogen, Beckman Coulter, Fujirebio To Develop Tau Pathology Blood Test For Alzheimer's Disease
30.07 14:50dpa-AFX: *BIOGEN, BECKMAN COULTER AND FUJIREBIO TO DEVELOP BLOOD-BASED BIOMARKERS FOR TAU PATHOLOGY IN AD
30.07 13:30dpa-AFX: GNW-Adhoc: Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease
26.07 15:47dpa-AFX: *BIOGEN -5,2% - EMA VERWEIGERT ZULASSUNG EINES ALZHEIMER-MITTELS
26.07 15:33dpa-AFX: Biogen Falls After Receiving Negative Opinion From CHMP For Lecanemab For Early Alzheimer's Disease
26.07 15:04dpa-AFX: ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab
26.07 15:04ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab
26.07 14:59dpa-AFX: ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab
26.07 13:30dpa-AFX: *EISAI AND BIOGEN : CHMP ISSUES NEGATIVE OPINION ON LECANEMAB FOR EARLY ALZHEIMER'S DISEASE
26.07 13:20dpa-AFX: GNW-Adhoc: Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
24.07 12:56dpa-AFX: Sage Therapeutics, Biogen Say Phase 2 KINETIC 2 Study Of SAGE-324 In Essential Tremor Fails

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH